SBI Securities’s Matinas BioPharma MTNB Stock Holding History

SBI Securities’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7	Hold	1	–	–	﹤0.01%	3947
2026 Q1	$6	Hold	1	–	–	﹤0.01%	3900
2025 Q4	$6	Hold	1	–	–	﹤0.01%	3920
2025 Q3	$21	Hold	1	–	–	﹤0.01%	3911
2025 Q2	$10	Hold	1	–	–	﹤0.01%	4012
2025 Q1	$7	Hold	1	–	–	﹤0.01%	4001
2024 Q4	$6	Buy	+1	New	+$23	﹤0.01%	3980

Other funds holding MTNB

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

HIW

Holos Integrated Wealth Kennett Square, Pennsylvania $214M AUM 14.99% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return

SBI Securities's MTNB Position: Q2 2026 in Review

SBI Securities held its Matinas BioPharma (MTNB) position steady in Q2 2026 at 1 share worth $7. The position accounts for ﹤0.01% of the portfolio, ranked #3947.

SBI Securities first reported a position in MTNB in Q4 2024 and has held it in 7 quarters since. The position peaked at $21 in Q3 2025. 23 funds tracked by Wall St. Rank hold MTNB as of Q2 2026.

SBI Securities held 1 share of Matinas BioPharma worth $7 as of Q2 2026.
SBI Securities left its Matinas BioPharma share count unchanged in Q2 2026.
Matinas BioPharma made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3947 holding.
SBI Securities first reported a position in Matinas BioPharma in Q4 2024 and has held it in 7 quarters since.
SBI Securities's Matinas BioPharma position peaked at $21 in Q3 2025.
23 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.